Matrixyl
Palmitoyl Pentapeptide-4
Matrixyl (Palmitoyl Pentapeptide-4) is a healing & recovery research compound. Topical collagen-stimulating peptide — signals fibroblasts to boost collagen, elastin and hyaluronic-acid synthesis for skin firmness.
Matrixyl quick facts
| Reported research dose (Topical) | Topical, as directed |
| Route | Topical |
| Frequency | 1-2x Daily (topical) |
| Half-life | N/A (topical) |
| Forms | Topical |
| Evidence level | Cosmetic/topical human |
| Other forms available | Injectable — dosed differently |
The collagen-builder of the topical peptides — pairs with GHK-Cu for skin.
How Matrixyl works
Topical collagen-stimulating peptide — signals fibroblasts to boost collagen, elastin and hyaluronic-acid synthesis for skin firmness.
Proposed benefits
Collagen synthesis, fine lines and skin-texture support (topical cosmetic).
Where to get Matrixyl
The evidence for Matrixyl
Graded by what exists behind each claim.
✅ Clinically validated
- Among the best-evidenced cosmeceutical peptides. Controlled studies of palmitoyl pentapeptide-4 report increased collagen I, III and fibronectin with measurable reductions in wrinkle depth, and it has been compared favorably against retinol with better tolerability.
📊 Correlative data
- Two decades of wide cosmetic use. Reported experience is of a slow, cumulative improvement in skin texture — consistent with collagen turnover timescales rather than an immediate effect.
🧪 Theoretical / extrapolated
- A palmitoylated fragment of type I collagen. It acts as a feedback signal: collagen fragments are what the skin produces when collagen breaks down, so applying them convinces fibroblasts that repair is needed.
- Unlike the neuropeptides above, its target — the fibroblast in the upper dermis — is reachable, which is the mechanistic reason its evidence is stronger than Argireline's.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Matrixyl actually does
Matrixyl is palmitoyl pentapeptide-4: a C16 fatty acid amide-bonded to Lys-Thr-Thr-Lys-Ser. The Cosmetic Ingredient Review defines the ingredient as the reaction product of palmitic acid with a five-residue peptide of lysine, serine and threonine CIR Expert Panel (Cosmetic Ingredient Review) 2012, and the site’s own label for it is correct.
Where the pentapeptide comes from, and why that is the whole idea. Type I collagen is not secreted as collagen. It is secreted as procollagen, with a large C-terminal propeptide that gets enzymatically clipped off before the triple helices pack into a fibril. KTTKS is residues 212–216 of that discarded C-propeptide, and it was identified as the minimum active subfragment of it Katayama 1993. So this is a matrikine in the strict sense: a fragment your own skin generates when collagen is being made and when collagen is being taken apart, read by the fibroblast as a signal that matrix production is wanted. Applying it is an attempt to forge that signal.
The chemistry, computed from the sequence. Free KTTKS is 563.64 Da, isoelectric point 10.81, and carries about +1.94 units of charge at blood pH — two lysines and a free N-terminal amine make it strongly cationic and strongly water-loving. Palmitoylation adds 238.41 Da for a total of 802.05 Da, and it does something the marketing never mentions: the acylation converts the N-terminal ammonium into a neutral amide, so the molecule loses roughly one unit of positive charge at the same time as it gains a 16-carbon tail. The polarity swing is much larger than the mass change suggests.
What the tail is actually for, and it is not simply grease. C16-KTTKS is a peptide amphiphile. Small-angle scattering and cryo-microscopy show it self-assembles in water into flat tapes with high beta-sheet content that take up Congo red, the classic amyloid-type stain Castelletto 2013. And when the collagen response was measured against concentration in human dermal and corneal fibroblasts, stimulation appeared close to the critical aggregation concentration rather than rising smoothly from zero Jones 2013. Put those two results together and you get a mechanistic claim that no vendor page in this category makes: the species doing the work may be the assembly, not the monomer. If that is right, then concentration below the aggregation threshold buys nothing, a surfactant-heavy base can pull the tapes apart, and the dose-response curve should have a knee in it rather than a slope. Every one of those is testable and none of them has been tested in a finished product.
The formulation work points the same way. Loading N-palmitoyl-KTTKS into egg phosphatidylcholine vesicles — under 100 nm by reverse-phase evaporation, under 200 nm by thin-film evaporation, polydispersity under 0.20 — produced more collagen in 3T3-NIH fibroblasts than the free peptide, with 1 mM ascorbic acid as the positive control Vitali 2024. A carrier that changes the answer is a carrier that was doing something to the delivery, the assembly, or both.
Cell, rodent, human — and where it stops
Step one, human fibroblasts in a dish. The founding experiment took the C-terminal propeptide of type I collagen apart and found the pentapeptide at residues 212–216 to be the minimum fragment that still drove type I collagen, type III collagen and fibronectin production Katayama 1993. This is free KTTKS, not the palmitoylated version, and it is a 1993 result that the entire ingredient rests on.
Step two, rat tendon cells, which is where the numbers get specific. KTTKS on rat Achilles tendon cells raised alpha1(I) procollagen mRNA and increased TGF-beta in the conditioned medium in a dose-dependent way (p = 0.001); it also slowed the degradation of alpha1(I) procollagen mRNA (p = 0.021), assessed at 24 and 48 hours after transcription was blocked with alpha-amanitin, and cell viability by MTT was unaffected Tsai 2007. Note what that adds and what it does not: it is evidence for message stabilization rather than pure transcriptional switching, and it is tendon, in a rat, with the free peptide.
Step three, the palmitoylated molecule on fibroblasts, and a dose-response that misbehaves. Pal-KTTKS across 0 to 0.5 µM induced connective tissue growth factor and alpha-smooth muscle actin; at 0.1 µM the proportion of cells carrying alpha-SMA-positive stress fibers fell from 75 ± 7.1% to 38.6 ± 16.1% (n = 3, p < 0.05), while 0.5 µM was not significant Park 2017. A five-fold higher concentration doing less is exactly the shape you would predict if the active species is an aggregate whose geometry changes with concentration, and it is the single most overlooked number in this ingredient’s file.
Step four, rodents. Male Wistar rats, burn wounds, dressings of carboxylated cellulose enriched with pal-KTTKS with and without mesenchymal stem cells, renewed every 5 days and read at days 3, 7 and 14 Rasouli 2024. Wound closure, collagen deposition and angiogenesis were best in the arm that also carried stem cells — which means the peptide’s own contribution was not isolated by the design. It is a real animal result and it is not a clean one.
Step five, the human trial, which is genuinely the best in this cohort. 93 Caucasian women, 12 weeks, double-blind, split-face with left-right randomization, 3 ppm pal-KTTKS in a moisturizer against the identical moisturizer without it, reporting significant reduction in wrinkles and fine lines by quantitative image analysis and by expert grading, plus self-assessment Robinson 2005. Design matters here more than the result: split-face with a vehicle control is a strong format, and it was run by the company that sold the product. That is not a reason to discard it. It is a reason to say what it is.
The obstacle, and this time it can be done as arithmetic rather than as a shrug. The rule of thumb for skin is that molecules over 500 Da do not get through intact stratum corneum Bos 2000; pal-KTTKS is 802 Da, 60% over. Directly: across full-thickness hairless mouse skin, neither KTTKS nor pal-KTTKS was detected in the receptor solution at all, while pal-KTTKS was recovered from the layers themselves at 4.2 ± 0.7 µg/cm² in stratum corneum, 2.8 ± 0.5 in epidermis and 0.3 ± 0.1 in dermis; both peptides were degraded rapidly in skin, with the palmitoylated one more stable Choi 2014. Now do the sums nobody does. A leave-on product applied at the standard 2 mg/cm², at Robinson’s 3 ppm, puts 6 ng of peptide on each square centimetre. The stratum corneum figure in that permeation study, 4.2 µg/cm², is about 700 times the entire dose a 3-ppm cream applies — so the experiment was run far above cosmetic use levels and still nothing crossed. Take the dermal number at face value: 0.3 µg/cm² distributed through 1 cm² by 1 mm of dermis is about 3.7 µM. Scale that down by the same 700-fold to a real product and you land near 5 nM at the fibroblast, against the 100–500 nM range where the stress-fiber effect actually lived Park 2017. Twenty to a hundred times short, before counting proteolysis.
And the trial was still positive. That tension is the honest state of this ingredient, and there are only four ways out of it: the moisturizer base did the work; potency in living skin genuinely exceeds the culture concentration; the target is the dermo-epidermal junction and the upper papillary dermis rather than the depth the arithmetic assumes; or the amphiphile acts on the barrier itself rather than on a fibroblast. The reviews of this literature flag the same hole from the other side — the absence of penetration data was the headline gap in the KTTKS review Abu Samah 2011, and permeability is described as the dismissed necessity of the whole anti-wrinkle peptide field Mortazavi 2022.
Matrixyl pharmacokinetics — how much of it actually gets in
The card says N/A (topical), which is true and is where the thinking usually stops. Here is what is behind it.
What destroys it. Skin is full of proteases, and both KTTKS and pal-KTTKS are degraded rapidly in skin homogenate; the palmitoyl group slows that down without stopping it Choi 2014. So the relevant clock is not a plasma half-life, it is a residence time in a tissue that is actively digesting the molecule while it sits there.
The barrier, and the trap inside it. At 802.05 Da this molecule is over the 500 Da threshold Bos 2000, and the C16 chain creates a second problem on top of the size one. Raising lipophilicity helps a molecule partition into stratum corneum lipid and hurts its ability to leave that lipid for the watery viable epidermis underneath. The measured distribution matches: 4.2 µg/cm² stuck in the stratum corneum against 0.3 in dermis, and nothing at all in the receptor fluid Choi 2014. The stratum corneum is behaving as a reservoir, not a conduit.
How much material is actually involved. At 2 mg/cm² and 3 ppm, a whole face of roughly 400 cm² receives about 2.4 µg of peptide per application. Applied twice a day across a 12-week course — 168 applications — the total peptide a person is exposed to is on the order of 0.4 mg — less than half a milligram, spread over three months, most of it never leaving the dead layer. Any claim about this ingredient has to be a claim about what that quantity can do.
The label arithmetic that catches people. A bottle saying it contains 3% or 8% Matrixyl is quoting the percentage of the supplier’s premix, which is a dilute solution of the peptide in water and glycol, not 3% peptide. The one double-blind trial used 0.0003% of the actual molecule Robinson 2005. Anybody comparing products on the front-of-pack number is comparing premix, and the manufacturers do not publish the dilution.
There is no other route. No oral, intravenous or subcutaneous pharmacokinetic study of pal-KTTKS exists in any species, so terms like bioavailability and clearance have no measured value here at all.
What would have to be true, and how you would know it was not
What to watch. A photograph, under fixed lighting, at a fixed distance, with the same lens and the same time of day, at week 0, week 6 and week 12 — crow’s feet at rest and at full smile, because the two respond differently and only one of them is collagen. A corneometer reading from the same spot on the cheek at each visit is the second number, and it is there to be a control rather than a result. A subjective impression at four weeks is not a read-out; the trial that found an effect needed 12 weeks and 93 people to see it Robinson 2005.
How long before it means anything. Twelve weeks, minimum. Dermal collagen turnover is measured in months, and the mRNA-stability mechanism the tendon work describes Tsai 2007 is a slow accumulation rather than a switch. Anything visible in the first fortnight is hydration and light.
What will fool you. The vehicle. Every published positive result for this molecule is a peptide-in-moisturizer against the same moisturizer, and the moisturizer alone improves the appearance of fine lines within days. The second trap is seasonal — skin measured in February and again in May has changed for reasons that have nothing to do with the bottle.
Prediction 1, and it cuts against the product. Run the identical base with and without the peptide on left and right cheeks. At week 4 the two halves will be indistinguishable to a corneometer and to the eye. If a user reports a difference at week 4, the difference is not collagen, because 0.4 mg of peptide over 12 weeks cannot build measurable dermal matrix in 28 days.
Prediction 2, the one nobody has run and the one that would settle the mechanism. Formulate the same base at 1 ppm, 3 ppm and 30 ppm. If the response is proportional, the monomer is the active species. If it is flat and then jumps — a knee rather than a slope — that is the aggregation threshold showing itself, exactly as the fibroblast concentration series implied Jones 2013 and as the non-monotonic stress-fiber result hinted Park 2017. This is a three-arm split-face study with a camera and it has never been published.
Prediction 3, against the compound again. Nothing in blood moves. hs-CRP, ApoB, a full metabolic panel — all flat, because neither peptide reached the receptor solution in the only permeation study that exists Choi 2014 and the total applied mass is under a milligram a quarter. If a blood marker does move during a course of this, look at what else changed, because it was not the cream.
What nobody has tested yet
Five experiments, in order of how much they would change what this page can say.
1. Nobody has measured the critical aggregation concentration of pal-KTTKS in an actual cosmetic base. It has been measured in water Castelletto 2013, and the collagen response tracks it Jones 2013. A finished serum contains surfactants, glycols and emulsifiers, all of which change aggregation. If the CAC in a real base sits above the use concentration, then a large fraction of the products on the market are selling a monomer that the fibroblast work suggests is the inactive form. A pyrene fluorescence assay in three commercial bases would answer it in an afternoon.
2. Nobody has tape-stripped human skin after a real product. The permeation data is hairless mouse skin at a concentration hundreds of times cosmetic use Choi 2014. Sequential tape strips plus mass spectrometry on human volunteers, after 3 ppm applied normally, would give the first honest depth profile for this molecule in the species that buys it.
3. Nobody has compared pal-KTTKS with free KTTKS in a person at equal molarity. The entire justification for the palmitoyl group is delivery, and the comparison that would prove it — two halves of one face, equimolar, 12 weeks — has never been published in the three decades since the pentapeptide was described Katayama 1993.
4. Nobody has taken the liposomal form into a human. Vesicle encapsulation beat the free peptide on fibroblast collagen production Vitali 2024, which is the first mechanistic reason in years to expect a bigger effect. Whether it survives contact with a person is unknown, and the formulation is not proprietary.
5. Nobody has independently replicated the 2005 trial. Twenty-one years, an ingredient in thousands of products, and the controlled human evidence is still one company’s split-face study Robinson 2005. An academic dermatology department could repeat it for the cost of the cream.
Matrixyl — its own safety story, not its class's
The class block on this page is written for injectable repair peptides and warns about angiogenesis. That warning is not this molecule’s risk story, and the specific data runs the other way.
The fibrosis worry is backwards here. The obvious fear about a collagen-stimulating peptide is scarring. What was actually measured is that 0.1 µM pal-KTTKS reduced the proportion of fibroblasts carrying alpha-smooth-muscle-actin stress fibers, from 75% to 39% Park 2017 — myofibroblast conversion is the cell state that drives scar contraction, and this pushed it down rather than up. One in-vitro result is not a safety clearance, but it is more than the generic warning it replaces, and it points the opposite way.
The risk that is real and is chemical rather than biological. This is a surfactant. A 16-carbon tail on a cationic pentapeptide is, structurally, a mild detergent, and detergents at high concentration sting, disrupt barrier lipids and provoke irritant reactions. That is the mechanism behind the tingling people report from high-percentage peptide serums, and it is dose-dependent in a way the peptide effect may not be.
The genuinely open question, which belongs in a safety section and has never been put in one. C16-KTTKS assembles into beta-sheet tapes that stain with Congo red Castelletto 2013. That is a description of an amyloid-type structure being deliberately deposited into the stratum corneum twice a day for years. Nobody has looked for persistent peptide assemblies in the corneum of long-term users, and nobody has asked whether they matter. The stratum corneum is dead tissue that sheds every fortnight, which is the strongest argument that it does not matter — but that is an argument, not a measurement.
What to do about layering, specifically. This peptide carries no metal, so the copper-redox problem that governs the copper-peptide cards in this Vault does not apply to it. The interaction that does apply is physical: a low-pH acid step and a surfactant cleanser both attack the assembly the activity may depend on. Applying it to clean, dry skin and leaving it alone for a few minutes is not a ritual, it is the only formulation advice this mechanism actually supports.
Sources read for this page
- Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem 1993 · PMID 8486721
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci 2005 · PMID 18492182
- Choi YL, Park EK, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul) 2014 · PMID 25143811
- Abu Samah NH, Heard CM. Topically applied KTTKS: a review. Int J Cosmet Sci 2011 · PMID 21535443
- Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm 2013 · PMID 23320752
- Castelletto V, Hamley IW, Perez J, Abezgauz L, Danino D. Self-assembly of palmitoyl lipopeptides used in skin care products. Langmuir 2013 · PMID 23822110
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 · PMID 10839713
- Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci 2022 · PMID 35302659
- Tsai WC, Tang FT, Wong MK, Pang JH. The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cells. J Orthop Res 2007 · PMID 17593541
- Park H, Kim S, Kim S, Song Y, Seung K, Hong D, Khang G, Lee D. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and alpha-Smooth Muscle Actin Expression. Tissue Eng Regen Med 2017 · PMID 30603464
- Rasouli M, Safari F, Sobhani N, Bagheri M, Kavosh A, Roosta Y. Mesenchymal stem cell therapy using Pal-KTTKS-enriched carboxylated cellulose improves burn wound in rat model. Arch Dermatol Res 2024 · PMID 38850353
- Vitali A, Stringaro A, Colone M, Muntiu A, Rinaldi F, Marianecci C, Carafa M. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics 2024 · PMID 38399273
- CIR Expert Panel (Cosmetic Ingredient Review). Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics (scientific literature review). Cosmetic Ingredient Review 2012
Matrixyl — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Matrixyl — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
Applied topically, this has no systemic exposure worth speaking of — so there is nothing to interact with anything you take, and no blood marker it could move. That is the honest answer rather than an empty section. The real interactions for a topical are layering ones: what you put on before and after it, and at what pH.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Matrixyl in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Matrixyl
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Matrixyl — frequently asked questions
What is Matrixyl?
Matrixyl (Palmitoyl Pentapeptide-4) is a healing & recovery research compound. Topical collagen-stimulating peptide — signals fibroblasts to boost collagen, elastin and hyaluronic-acid synthesis for skin firmness.
Is the full Matrixyl protocol on this page?
The reported research dose is on this page, along with how Matrixyl works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Matrixyl?
Matrixyl has an approximate half-life of N/A (topical), which is part of what determines how often it's dosed.
What's the evidence behind Matrixyl?
Current evidence level: Cosmetic/topical human. Matrixyl is offered for research purposes only and is not an approved medicine.
Matrixyl inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Matrixyl is used for
Matrixyl appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
Matrixyl is the collagen arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.